FDA says current dose of GSK, Vir COVID therapy likely not effective against BA.2 variant

(Reuters) - The U.S. health regulator has determined that the current authorized dose of GlaxoSmithKline Plc and Vir Biotechnology's antibody-based CO...

Related Keywords

Bengaluru ,Karnataka ,India ,Manojna Maddipatla ,Shailesh Kuber ,Glaxosmithkline Plc ,Reuters ,Vir Biotechnology , ,